NQF #0031 Breast Cancer Screening

NATIONAL QUALITY FORUM

Measure Submission and Evaluation Worksheet 5.0

This form contains the information submitted by measure developers/stewards, organized according to NQF’s measure evaluation criteria and process. The evaluation criteria, evaluation guidance documents, and a blank online submission form are available on the submitting standards web page.

<table>
<thead>
<tr>
<th>NQF #: 0031</th>
<th>NQF Project: Population Health: Prevention Project</th>
</tr>
</thead>
<tbody>
<tr>
<td>(for Endorsement Maintenance Review)</td>
<td></td>
</tr>
<tr>
<td>Original Endorsement Date: Aug 10, 2009 Most Recent Endorsement Date: Aug 10, 2009</td>
<td></td>
</tr>
</tbody>
</table>

**BRIEF MEASURE INFORMATION**

De.1 Measure Title: Breast Cancer Screening

Co.1 Measure Steward: National Committee for Quality Assurance

De.2 Brief Description of Measure: Percentage of eligible women 40-69 who receive a mammogram in a two year period

2a1.1 Numerator Statement: One or more mammograms during the measurement year or the year prior to the measurement year.

2a1.4 Denominator Statement: Women 42–69 years of age

2a1.8 Denominator Exclusions: Optional Exclusion: Women who had a bilateral mastectomy or for whom there is evidence of two unilateral mastectomies.

1.1 Measure Type: Process

2a1.25-26 Data Source: Administrative claims, Electronic Clinical Data : Electronic Health Record, Paper Records

2a1.33 Level of Analysis: Clinician : Group/Practice, Clinician : Individual, Health Plan

1.2-1.4 Is this measure paired with another measure? No

De.3 If included in a composite, please identify the composite measure (title and NQF number if endorsed): 

**STAFF NOTES (issues or questions regarding any criteria)**

Comments on Conditions for Consideration:

Is the measure untested? Yes ☐ No ☐ If untested, explain how it meets criteria for consideration for time-limited endorsement:

1a. Specific national health goal/priority identified by DHHS or NPP addressed by the measure (check De.5):

5. Similar/related endorsed or submitted measures (check 5.1):

Other Criteria:

Staff Reviewer Name(s):

1. IMPACT, OPPORTUNITY, EVIDENCE - IMPORTANCE TO MEASURE AND REPORT

Importance to Measure and Report is a threshold criterion that must be met in order to recommend a measure for endorsement. All three subcriteria must be met to pass this criterion. See guidance on evidence. Measures must be judged to be important to measure and report in order to be evaluated against the remaining criteria. (evaluation criteria)

1a. High Impact: H ☐ M ☐ L ☐ I ☐
The measure directly addresses a specific national health goal/priority identified by DHHS or NPP, or some other high impact aspect of healthcare.

De.4 Subject/Topic Areas (Check all the areas that apply): Cancer, Cancer: Breast, Prevention
De.5 Cross Cutting Areas (Check all the areas that apply): Population Health

1a.1 Demonstrated High Impact Aspect of Healthcare: Affects large numbers, Severity of illness

1a.2 If “Other,” please describe:

1a.3 Summary of Evidence of High Impact (Provide epidemiologic or resource use data):
Breast cancer is one of the most common types of cancers accounting for a quarter of all the new cancer diagnoses in American women.1 Breast cancer is the second top cause of cancer deaths in women (after lung cancer) with nearly 40,000 estimated deaths in 2010. 2 Deaths of breast cancer patients have decreased over the years, thanks to early detection using mammography. On average, mammography will detect about 80-90 percent of breast cancers in women without symptoms. 2 Based on evidence, screening mammography in women aged 40 to 70 years decreases breast cancer mortality with higher benefit in older women.4 About 70-80 percent of breast cancers occur in women who have no family history of breast cancer. These occur due to genetic abnormalities that happen as a result of the aging process and life in general. 5 Mammogram screening has demonstrated reductions in breast cancer mortality and there is a clear connection between developing breast cancer and age.6,7 For women aged 39 to 40 years, trials of mammography screening indicate a statistically significant 15% reduction in breast cancer mortality for women randomly assigned to screening versus those assigned to controls. These results are similar to those for women aged 50 to 59 years but less than those for women aged 60 to 69 years. For women aged 70 years or older, results from the Swedish Two-County trial (26) of women aged 70 to 74 years indicate no mortality reduction. However, these results are limited by including only a few women from 1 sample. Interpreting trial results stratified by age requires caution because most age-specific results are subanalyses of trials designed for different purposes.

The meta-analysis of mammography screening trials indicates breast cancer mortality sufficient benefit for all age groups from 39 to 69 years, with insufficient data for older women. False-positive results are common in all age groups and lead to additional imaging and biopsies. Women aged 40 to 49 years experience the highest rate of additional imaging, whereas their biopsy rate is lower than that for older women. Mammography screening at any age is a tradeoff of a continuum of benefits and harms. The ages at which this tradeoff becomes acceptable to individuals and society are not clearly resolved by the available evidence.8

### 1b. Opportunity for Improvement: H □ M □ L □ I □
(There is a demonstrated performance gap - variability or overall less than optimal performance)

#### 1b.1 Briefly explain the benefits (improvements in quality) envisioned by use of this measure:
The intent of the measure is to improve secondary prevention of breast cancer in order to catch disease when it is early and more amenable to treatment. Breast cancer treatment costs in the U.S. total nearly $7 billion per year, of which $2 billion is spent on late-stage treatment. Low-income women are less likely to have had a mammogram within the past two years, increasing their risk of late-stage diagnosis and decreasing their chance of survival.

Numerous trials and evaluations have clearly shown that mammography reduces the risk of dying from breast cancer. Early detection of breast cancer by mammography may lead to greater range of treatment options including less-aggressive surgery and less-invasive therapy. The five-year survival rate for women who are diagnosed early is 98 percent compared to late-diagnosed breast cancer survival rate of only 23 percent.

#### 1b.2 Summary of Data Demonstrating Performance Gap (Variation or overall less than optimal performance across providers):

[For Maintenance – Descriptive statistics for performance results for this measure - distribution of scores for measured entities by quartile/decile, mean, median, SD, min, max, etc.]

<table>
<thead>
<tr>
<th></th>
<th>Commercial Health Plan Rates</th>
<th>Medicare Health Plans</th>
<th>Medicaid Health Plans</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>BCS - Rate - Total</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N</td>
<td>244</td>
<td>253</td>
<td>258</td>
</tr>
<tr>
<td>MEAN</td>
<td>71.3</td>
<td>70.2</td>
<td>69.1</td>
</tr>
<tr>
<td>STDEV</td>
<td>6.08</td>
<td>6.18</td>
<td>5.94</td>
</tr>
<tr>
<td>STDERR</td>
<td>0.39</td>
<td>0.39</td>
<td>0.37</td>
</tr>
<tr>
<td>MIN</td>
<td>55.1</td>
<td>47.5</td>
<td>52.2</td>
</tr>
<tr>
<td>MAX</td>
<td>90.0</td>
<td>85.1</td>
<td>84.4</td>
</tr>
<tr>
<td>P10</td>
<td>64.2</td>
<td>62.7</td>
<td>61.9</td>
</tr>
<tr>
<td>P25</td>
<td>67.0</td>
<td>66.2</td>
<td>64.9</td>
</tr>
<tr>
<td>P50</td>
<td>70.7</td>
<td>70.0</td>
<td>68.5</td>
</tr>
<tr>
<td>P75</td>
<td>75.3</td>
<td>74.2</td>
<td>73.5</td>
</tr>
<tr>
<td>P90</td>
<td>80.1</td>
<td>78.7</td>
<td>78.2</td>
</tr>
</tbody>
</table>

See Guidance for Definitions of Rating Scale: H=High; M=Moderate; L=Low; I=Insufficient; NA=Not Applicable
P50  52  50.5  50
P75  59.6  57.4  56.1
P90  63.8  63  61.2

1b.3 Citations for Data on Performance Gap: [For Maintenance – Description of the data or sample for measure results reported in 1b.2 including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included]
The data are performance rates from all health plans participating in the HEDIS measure set. There were 2108 plan submissions for this measure. NCQA collects data directly from Health Plan Organizations and Preferred Provider Organizations via a data submission portal - the Interactive Data Submission System (IDSS). NCQA assigns a sub-ID by an accreditable identity based on the legal entity and management structure that supports the product lines/products that NCQA accredits. Each accreditation is legally accountable entity provides to members and representation of an organization and delivery structure that is meaningful to members.

1b.4 Summary of Data on Disparities by Population Group: [For Maintenance – Descriptive statistics for performance results for this measure by population group]
After years of disparities, African American women and white women now have the same rate of mammography use. In 2008, 68 percent of African American women and 68 percent of white women had a mammogram within the past two years. Hispanic/Latina, Asian American and Native American have lower rates of breast cancer screening compared to African American and white women (62 percent of Hispanic/Latina women, 65 percent of Asian American women and 55 percent of Native American women had a mammogram in the past two years). With less screening, women may be getting diagnosed later, lowering their chances for survival.

The reasons behind these differences in mammography rates are unclear. Women have reported that costs and lack of insurance, access to care or a usual health care provider are barriers to mammography.

1b.5 Citations for Data on Disparities Cited in 1b.4: [For Maintenance – Description of the data or sample for measure results reported in 1b.4 including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included]

1c. Evidence (Measure focus is a health outcome OR meets the criteria for quantity, quality, consistency of the body of evidence.)
Is the measure focus a health outcome? Yes  No
If not a health outcome, rate the body of evidence.

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Quality</th>
<th>Consistency</th>
<th>Does the measure pass subcriterion1c?</th>
</tr>
</thead>
<tbody>
<tr>
<td>M-H</td>
<td>M-H</td>
<td>M-H</td>
<td>Yes</td>
</tr>
<tr>
<td>L</td>
<td>M-H</td>
<td>M</td>
<td>Yes IF additional research unlikely to change conclusion that benefits to patients outweigh harms: otherwise No</td>
</tr>
<tr>
<td>M-H</td>
<td>L</td>
<td>M-H</td>
<td>Yes IF potential benefits to patients clearly outweigh potential harms: otherwise No</td>
</tr>
<tr>
<td>L-M-H</td>
<td>L-M-H</td>
<td>L</td>
<td>No</td>
</tr>
</tbody>
</table>

Health outcome – rationale supports relationship to at least one healthcare structure, process, intervention, or service

1c.1 Structure-Process-Outcome Relationship (Briefly state the measure focus, e.g., health outcome, intermediate clinical outcome, process, structure; then identify the appropriate links, e.g., structure-process-health outcome; process-health outcome; intermediate clinical outcome-health outcome):
Mammography screenings aid practitioners in making decisions about appropriate obstetric and gynecologic care.

1c.2-3 Type of Evidence (Check all that apply):
Clinical Practice Guideline
1c.4 Directness of Evidence to the Specified Measure (State the central topic, population, and outcomes addressed in the body of evidence and identify any differences from the measure focus and measure target population):
This measure does not differ in focus from the body of evidence.

1c.5 Quantity of Studies in the Body of Evidence (Total number of studies, not articles): See USPSTF guideline report

1c.6 Quality of Body of Evidence (Summarize the certainty or confidence in the estimates of benefits and harms to patients across studies in the body of evidence resulting from study factors. Please address: a) study design/flaws; b) directness/indirectness of the evidence to this measure (e.g., interventions, comparisons, outcomes assessed, population included in the evidence); and c) imprecision/wide confidence intervals due to few patients or events): High

1c.7 Consistency of Results across Studies (Summarize the consistency of the magnitude and direction of the effect): Consistent

1c.8 Net Benefit (Provide estimates of effect for benefit/outcome; identify harms addressed and estimates of effect; and net benefit - benefit over harms):
The USPSTF determined there was a positive net benefit for breast cancer screening.

1c.9 Grading of Strength/Quality of the Body of Evidence. Has the body of evidence been graded? Yes

1c.10 If body of evidence graded, identify the entity that graded the evidence including balance of representation and any disclosures regarding bias: USPSTF

1c.11 System Used for Grading the Body of Evidence: USPSTF

1c.12 If other, identify and describe the grading scale with definitions:

1c.13 Grade Assigned to the Body of Evidence: The USPSTF recommends biennial screening mammography for women aged 50 to 74 years. Grade B.

1c.14 Summary of Controversy/Contradictory Evidence: Age Ranges: Major guidelines differ regarding the age at which women should begin screening. The USPSTF’s 2009 guideline recommends raising the age at which women begin screening from 40 to 50 years (a change from their 2002 guideline). Other guidelines, such as the American Cancer Society, recommend screening begin earlier.

Overdiagnosis: The harm caused by over diagnosis has also been debated by researchers. However, their magnitude and effect are difficult to measure. The risks associated with over diagnosis include women being treated with measures like chemotherapy, radiation and surgery for tumors that do not need treating. Estimates of the magnitude of overdiagnosis vary depending on the analytic approach used. These estimates are difficult to apply because, for individual women, it is not known which types of cancer will progress, how quickly cancer will advance, and expected lifetimes.

1c.15 Citations for Evidence other than Guidelines (Guidelines addressed below):


1c.16 Quote verbatim, the specific guideline recommendation (Including guideline # and/or page #):
U.S. Preventive Services Task Force (2009)
Grade: B recommendation. The USPSTF recommends biennial screening mammography for women aged 50 to 74 years.
Grade: C recommendation. The decision to start regular, biennial screening mammography before the age of 50 years should be an individual one and take patient context into account, including the patient’s values regarding specific benefits and harms.
Grade: I Statement. The USPSTF concludes that the current evidence is insufficient to assess the additional benefits and harms of screening mammography in women 75 years or older.
Grade: D recommendation. The USPSTF recommends against teaching breast self-examination (BSE).

Grade: I Statement. The USPSTF concludes that the current evidence is insufficient to assess the additional benefits and harms of clinical breast examination (CBE) beyond screening mammography in women 40 years or older.

Grade: I Statement. The USPSTF concludes that the current evidence is insufficient to assess the additional benefits and harms of either digital mammography or magnetic resonance imaging (MRI) instead of film mammography as screening modalities for breast cancer.

American Cancer Society (2009)
Recommend annual screening using mammography and clinical breast examination for all women beginning at age 40.

American College of Radiology (2009)
Recommend annual screening using mammography and clinical breast examination for all women beginning at age 40.

American College of Obstetricians and Gynecologists (2009)
Recommend:
- Screening mammography every 1-2 years for women aged 40-49 years
- Screening mammography every year for women age 50 or older
- BSE; BSE has the potential to detect palpable breast cancer and can be recommended.


1c.18 National Guideline Clearinghouse or other URL: http://www.guideline.gov/content.aspx?id=3990#Section427

1c.19 Grading of Strength of Guideline Recommendation. Has the recommendation been graded? Yes

1c.20 If guideline recommendation graded, identify the entity that graded the evidence including balance of representation and any disclosures regarding bias: U.S. Preventive Services Task Force

1c.21 System Used for Grading the Strength of Guideline Recommendation: USPSTF

1c.22 If other, identify and describe the grading scale with definitions:

1c.23 Grade Assigned to the Recommendation: The USPSTF recommends biennial screening mammography for women aged 50 to 74 years. Grade B.

1c.24 Rationale for Using this Guideline Over Others: It is NCQA policy to use guidelines which are evidence-based, applicable to health care providers, and developed by a national specialty organization or government agency.

NCQA convened an expert panel of diverse stakeholders to review the guidelines and evidence for this measure. The panel determined the measure was scientifically sound using the full body of evidence and guidelines for this measure concept.

Based on the NQF descriptions for rating the evidence, what was the developer's assessment of the quantity, quality, and consistency of the body of evidence?

1c.25 Quantity: High 1c.26 Quality: High 1c.27 Consistency: High

Was the threshold criterion, Importance to Measure and Report, met? (1a & 1b must be rated moderate or high and 1c yes) Yes No
Provide rationale based on specific subcriteria:

For a new measure if the Committee votes NO, then STOP. For a measure undergoing endorsement maintenance, if the Committee votes NO because of 1b. (no opportunity for improvement), it may be considered for continued endorsement and all criteria need to be evaluated.

### 2. RELIABILITY & VALIDITY - SCIENTIFIC ACCEPTABILITY OF MEASURE PROPERTIES

Extent to which the measure, as specified, produces consistent (reliable) and credible (valid) results about the quality of care when implemented. *(evaluation criteria)*

Measure testing must demonstrate adequate reliability and validity in order to be recommended for endorsement. Testing may be conducted for data elements and/or the computed measure score. Testing information and results should be entered in the appropriate field. Supplemental materials may be referenced or attached in item 2.1. See guidance on measure testing.

**S.1 Measure Web Page** *(In the future, NQF will require measure stewards to provide a URL link to a web page where current detailed specifications can be obtained).* Do you have a web page where current detailed specifications for this measure can be obtained? No

**S.2 If yes, provide web page URL:** TBD

#### 2a. RELIABILITY. Precise Specifications and Reliability Testing: H M L I

<table>
<thead>
<tr>
<th><strong>2a1. Precise Measure Specifications.</strong> <em>(The measure specifications precise and unambiguous.)</em></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>2a1.1 Numerator Statement</strong> <em>(Brief, narrative description of the measure focus or what is being measured about the target population, e.g., cases from the target population with the target process, condition, event, or outcome)</em>:</td>
</tr>
<tr>
<td>One or more mammograms during the measurement year or the year prior to the measurement year.</td>
</tr>
</tbody>
</table>

| **2a1.2 Numerator Time Window** *(The time period in which the target process, condition, event, or outcome is eligible for inclusion)*: |
| December 31 of the measurement year. |

| **2a1.3 Numerator Details** *(All information required to identify and calculate the cases from the target population with the target process, condition, event, or outcome such as definitions, codes with descriptors, and/or specific data collection items/responses)*: |
| **Administrative Specification** |
| A woman had a mammogram if a submitted claim/encounter contains any of the following codes. |

| Codes to Identify Breast Cancer Screening: CPT: 76090-76092, 77055-77057, G0202, G0204, G0206, V76.11, V76.12 87.36, 87.37 0401, 0403 |

| **Medical Record Specification** |
| One or more mammograms during the measurement year or the year prior to the measurement year. The medical record must include the following documentation. |
| • A note indicating the date when the mammogram was performed, and |
| • The result or finding |

| **2a1.4 Denominator Statement** *(Brief, narrative description of the target population being measured)*: |
| Women 42–69 years of age |

| **2a1.5 Target Population Category** *(Check all the populations for which the measure is specified and tested if any)*: Adult/Elderly Care |

| **2a1.6 Denominator Time Window** *(The time period in which cases are eligible for inclusion)*: |
| December 31 of the measurement year. |

| **2a1.7 Denominator Details** *(All information required to identify and calculate the target population/denominator such as definitions, codes with descriptors, and/or specific data collection items/responses)*: |
| **Product lines:** Commercial, Medicaid, Medicare (report each product line separately) |
Ages: Women 42-69 years as of December 31 of the measurement year
Continuous Enrollment: The measurement year and the year prior to the measurement year
Allowable gap: No more than one gap of enrollment of up to 45 days during each year of continuous enrollment. To determine continuous enrollment for a Medicaid beneficiary for whom enrollment is verified monthly, the member may not have more than a 1-month gap in coverage during each year of continuous enrollment.
Anchor date: December 31 of the measurement year
Benefit: Medical
Event/diagnosis: None.

Medical Record Specification
A systematic sample drawn from the eligible population. Use the Medical Record Method or the Hybrid Method to identify the eligible population. Refer to the following sections in the General Guidelines.
- The Medical Record Method
- The Hybrid Method
- Sampling Methods

2a1.8 Denominator Exclusions (Brief narrative description of exclusions from the target population):
Optional Exclusion: Women who had a bilateral mastectomy or for whom there is evidence of two unilateral mastectomies.

2a1.9 Denominator Exclusion Details (All information required to identify and calculate exclusions from the denominator such as definitions, codes with descriptors, and/or specific data collection items/responses):
Table BCS-B: Codes to Identify Exclusions

Bilateral mastectomy
CPT: 19180, 19200, 19220, 19240, 19303-19307 WITH Modifier .50 or modifier code 09950*
ICD-9-CM Procedure: 85.42, 85.44, 85.46, 85.48

Unilateral mastectomy (members must have 2 separate occurrences on 2 different dates of service)
CPT: 19180, 19200, 19220, 19240, 19303-19307
ICD-9-CM Procedure: 85.41, 85.43, 85.45, 85.47

*.50 and 09950 modifier codes indicate the procedure was bilateral and performed during the same operative session.

Note: The purpose of this measure is to evaluate primary screening. Do not count biopsies, breast ultrasounds or MRIs for this measure because they are not appropriate methods for primary breast cancer screening.

2a1.10 Stratification Details/Variables (All information required to stratify the measure results including the stratification variables, codes with descriptors, definitions, and/or specific data collection items/responses):
N/A

2a1.11 Risk Adjustment Type (Select type. Provide specifications for risk stratification in 2a1.10 and for statistical model in 2a1.13):
No risk adjustment or risk stratification 2a1.12 If "Other," please describe:

2a1.13 Statistical Risk Model and Variables (Name the statistical method - e.g., logistic regression and list all the risk factor variables. Note - risk model development should be addressed in 2b4.):
N/A

2a1.14-16 Detailed Risk Model Available at Web page URL (or attachment). Include coefficients, equations, codes with descriptors, definitions, and/or specific data collection items/responses. Attach documents only if they are not available on a webpage and keep attached file to 5 MB or less. NQF strongly prefers you make documents available at a Web page URL. Please
NQF #0031 Breast Cancer Screening

2a1.17-18. **Type of Score**: Rate/proportion

2a1.19 **Interpretation of Score** *(Classifies interpretation of score according to whether better quality is associated with a higher score, a lower score, a score falling within a defined interval, or a passing score)*: Better quality = Higher score

2a1.20 **Calculation Algorithm/Measure Logic** *(Describe the calculation of the measure score as an ordered sequence of steps including identifying the target population; exclusions; cases meeting the target process, condition, event, or outcome; aggregating data; risk adjustment; etc.)*:

1. **Step 1. Determine the eligible population.** The eligible population is all members who satisfy all specified criteria, including any age, continuous enrollment, benefit, event, or anchor date enrollment requirement.
2. **Step 2. Search administrative systems to identify numerator events for all members in the eligible population.**
3. **Step 3. If applicable, for members for whom administrative data do not show a positive numerator event, search administrative data for an exclusion to the service/procedure being measured.**
   *Note: This step applies only to measures for which optional exclusions are specified and for which the organization has chosen to search for exclusions. The organization is not required to search for optional exclusions.*
4. **Step 4. Exclude from the eligible population members from step 3 for whom administrative system data identified an exclusion to the service/procedure being measured.**
5. **Step 5. Calculate the rate.**

2a1.21-23 **Calculation Algorithm/Measure Logic Diagram URL or attachment:**

2a1.24 **Sampling (Survey) Methodology**. If measure is based on a sample (or survey), provide instructions for obtaining the sample, conducting the survey and guidance on minimum sample size (response rate):

**Medical Record Specification**
A systematic sample drawn from the eligible population. Use the Medical Record Method or the Hybrid Method to identify the eligible population. Refer to the following sections in the General Guidelines.

- The Medical Record Method
- The Hybrid Method
- Sampling Methods

For this physician-level measure, we anticipate the entire population will be used in the denominator. If a sample is used, a random sample is ideal. NCQA’s work has indicated that a sample size of 30-50 patients would be necessary for a typical practice size of 2000 patients.

2a1.25 **Data Source** *(Check all the sources for which the measure is specified and tested)*. If other, please describe:
Administrative claims, Electronic Clinical Data : Electronic Health Record, Paper Records

2a1.26 **Data Source/Data Collection Instrument** *(Identify the specific data source/data collection instrument, e.g. name of database, clinical registry, collection instrument, etc.)*: Healthcare Effectiveness Data Information Set (HEDIS)

2a1.27-29 **Data Source/data Collection Instrument Reference Web Page URL or Attachment:**

2a1.30-32 **Data Dictionary/Code Table Web Page URL or Attachment:**
2a1.33 **Level of Analysis**  *(Check the levels of analysis for which the measure is specified and tested):*  
Clinician: Group/Practice, Clinician: Individual, Health Plan

2a1.34-35 **Care Setting** *(Check all the settings for which the measure is specified and tested):*  
Ambulatory Care: Clinician Office

2a2. **Reliability Testing.** *(Reliability testing was conducted with appropriate method, scope, and adequate demonstration of reliability.)*

2a2.1 **Data/Sample** *(Description of the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included):*  
HEDIS Health Plan performance data from 2010

2a2.2 **Analytic Method** *(Describe method of reliability testing & rationale):*  
Reliability was estimated by using the beta-binomial model. Beta-binomial is a better fit when estimating the reliability of simple pass/fail rate measures as is the case with most HEDIS® health plan measures. The beta-binomial model assumes the plan score is a binomial random variable conditional on the plan's true value that comes from the beta distribution. The beta distribution is usually defined by two parameters, alpha and beta. Alpha and beta can be thought of as intermediate calculations to get to the needed variance estimates. The beta distribution can be symmetric, skewed or even U-shaped. 
Reliability used here is the ratio of signal to noise. The signal in this case is the proportion of the variability in measured performance that can be explained by real differences in performance. A reliability of zero implies that all the variability in a measure is attributable to measurement error. A reliability of one implies that all the variability is attributable to real differences in performance. The higher the reliability score, the greater is the confidence with which one can distinguish the performance of one plan from another. A reliability score greater than or equal to 0.7 is considered very good.

2a2.3 **Testing Results** *(Reliability statistics, assessment of adequacy in the context of norms for the test conducted):*  
Reliability statistic for breast cancer screening:
- Commercial 2010: 0.997989
- Medicaid 2010: 0.993524
- Medicare 2010: 0.991807

2b. **VALIDITY. Validity, Testing, including all Threats to Validity:**  
H□ M□ L□ I□

2b1.1 **Describe how the measure specifications** *(measure focus, target population, and exclusions)* **are consistent with the evidence cited in support of the measure focus** *(criterion 1c)* **and identify any differences from the evidence:**  
The measure is aligned with current guidelines

2b2. **Validity Testing.** *(Validity testing was conducted with appropriate method, scope, and adequate demonstration of validity.)*

2b2.1 **Data/Sample** *(Description of the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included):*  
After careful review of the updated USPSTF recommendation, NCQA decided not to change the current HEDIS Breast Cancer Screening measure. There are conflicting interpretations of the evidence the Task Force and others used to revise their recommendations. This conflict is reflected in other guidelines, such as those from the National Cancer Institute and the American Cancer Society. Because NCQA quality measurement advisory groups rely on evidence-based guidelines to develop our measures, we are awaiting consensus by guideline development authorities before deciding how best to proceed. Additionally, under the new health reform law, insurers must waive cost sharing for mammography based on age ranges in the prior Task Force guideline, which was the basis for our current Breast Cancer Screening measure.

2b2.2 **Analytic Method** *(Describe method of validity testing and rationale; if face validity, describe systematic assessment):*  
NCQA tested the measure for face validity using a panel of stakeholders with specific expertise in measurement and women's health. This panel included representatives from key stakeholder groups, including the American Cancer Society, Health Dialog, family physicians, health plans, state and researchers (See list of members of measure advisory panel for Breast Cancer Screening). Experts reviewed the results of the field test and assessed whether the results were consistent with expectations, whether the measure represented quality care, and whether we were measuring the most important aspect of care in this area.
### 2b2.3 Testing Results

(Statistical results, assessment of adequacy in the context of norms for the test conducted; if face validity, describe results of systematic assessment):

This measure was deemed valid by the expert panel.

### POTENTIAL THREATS TO VALIDITY

(All potential threats to validity were appropriately tested with adequate results.)

### 2b3. Measure Exclusions

(Exclusions were supported by clinical evidence in 1c or appropriately tested with results demonstrating the need to specify them.)

### 2b3.1 Data/Sample for analysis of exclusions

(Description of the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included):

NCQA currently allows health plans for optional exclusion to their results. NCQA does not conduct the annual analysis applied to a sample. In measure development, field testing and any re-analysis for update, we investigate and validate the effect reliability exclusion applied to the eligible denominator.

### 2b3.2 Analytic Method

(Describe type of analysis and rationale for examining exclusions, including exclusion related to patient preference):

N/A

### 2b3.3 Results

(Provide statistical results for analysis of exclusions, e.g., frequency, variability, sensitivity analyses):

N/A

### 2b4. Risk Adjustment Strategy

(For outcome measures, adjustment for differences in case mix (severity) across measured entities was appropriately tested with adequate results.)

### 2b4.1 Data/Sample

(Description of the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included):

N/A

### 2b4.2 Analytic Method

(Describe methods and rationale for development and testing of risk model or risk stratification including selection of factors/variables):

N/A

### 2b4.3 Testing Results

(Statistical risk model: Provide quantitative assessment of relative contribution of model risk factors; risk model performance metrics including cross-validation discrimination and calibration statistics, calibration curve and risk decile plot, and assessment of adequacy in the context of norms for risk models. Risk stratification: Provide quantitative assessment of relationship of risk factors to the outcome and differences in outcomes among the strata):

N/A

### 2b4.4 If outcome or resource use measure is not risk adjusted, provide rationale and analyses to justify lack of adjustment:

The measure assesses breast cancer in a general population of women; risk adjustment is not indicated. The measure is stratified by gender, age and product line.

### 2b5. Identification of Meaningful Differences in Performance

(The performance measure scores were appropriately analyzed and discriminated meaningful differences in quality.)

### 2b5.1 Data/Sample

(Describe the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included):

Data analysis demonstrates that methods for scoring and analysis of the specified measure allow for identification of statistically significant and practically/clinically meaningful differences in performance.

### 2b5.2 Analytic Method

(Describe methods and rationale to identify statistically significant and practically/meaningfully differences in performance):

Comparison of means and percentiles; analysis of variance against established benchmarks

### 2b5.3 Results

(Provide measure performance results/scores, e.g., distribution by quartile, mean, median, SD, etc.; identification of
statistically significant and meaningfully differences in performance):  

### Commercial Health Plan Rates  

<table>
<thead>
<tr>
<th>BCS - Rate - Total</th>
<th>2009</th>
<th>2008</th>
<th>2007</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>244</td>
<td>253</td>
<td>258</td>
</tr>
<tr>
<td>MEAN</td>
<td>71.3</td>
<td>70.2</td>
<td>69.1</td>
</tr>
<tr>
<td>STDEV</td>
<td>6.08</td>
<td>6.18</td>
<td>5.94</td>
</tr>
<tr>
<td>STDERR</td>
<td>0.39</td>
<td>0.39</td>
<td>0.37</td>
</tr>
<tr>
<td>MIN</td>
<td>55.1</td>
<td>47.5</td>
<td>52.2</td>
</tr>
<tr>
<td>MAX</td>
<td>90</td>
<td>85.1</td>
<td>84.4</td>
</tr>
<tr>
<td>P10</td>
<td>64.2</td>
<td>62.7</td>
<td>61.9</td>
</tr>
<tr>
<td>P25</td>
<td>67.0</td>
<td>66.2</td>
<td>64.9</td>
</tr>
<tr>
<td>P50</td>
<td>70.7</td>
<td>70</td>
<td>68.5</td>
</tr>
<tr>
<td>P75</td>
<td>75.3</td>
<td>74.2</td>
<td>73.5</td>
</tr>
<tr>
<td>P90</td>
<td>80.1</td>
<td>78.7</td>
<td>78.2</td>
</tr>
</tbody>
</table>

### Medicare Health Plans  

<table>
<thead>
<tr>
<th>BCS - Rate - Total</th>
<th>2009</th>
<th>2008</th>
<th>2007</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>290</td>
<td>255</td>
<td>229</td>
</tr>
<tr>
<td>MEAN</td>
<td>69.3</td>
<td>68</td>
<td>67.3</td>
</tr>
<tr>
<td>STDEV</td>
<td>10.0</td>
<td>11.2</td>
<td>11.7</td>
</tr>
<tr>
<td>STDERR</td>
<td>0.59</td>
<td>0.7</td>
<td>0.77</td>
</tr>
<tr>
<td>MIN</td>
<td>37.8</td>
<td>13.9</td>
<td>19</td>
</tr>
<tr>
<td>MAX</td>
<td>94.7</td>
<td>95.2</td>
<td>90.4</td>
</tr>
<tr>
<td>P10</td>
<td>55.7</td>
<td>53.2</td>
<td>52.3</td>
</tr>
<tr>
<td>P25</td>
<td>62.5</td>
<td>60.5</td>
<td>60.7</td>
</tr>
<tr>
<td>P50</td>
<td>69.8</td>
<td>67.8</td>
<td>68</td>
</tr>
<tr>
<td>P75</td>
<td>75.6</td>
<td>75.2</td>
<td>75.1</td>
</tr>
<tr>
<td>P90</td>
<td>82.7</td>
<td>82.9</td>
<td>83.5</td>
</tr>
</tbody>
</table>

### Medicaid Health Plans  

<table>
<thead>
<tr>
<th>BCS - Rate - Total</th>
<th>2009</th>
<th>2008</th>
<th>2007</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>144</td>
<td>137</td>
<td>138</td>
</tr>
<tr>
<td>MEAN</td>
<td>52.4</td>
<td>50.8</td>
<td>49.8</td>
</tr>
<tr>
<td>STDEV</td>
<td>10.2</td>
<td>10.3</td>
<td>9.36</td>
</tr>
<tr>
<td>STDERR</td>
<td>0.85</td>
<td>0.88</td>
<td>0.8</td>
</tr>
<tr>
<td>MIN</td>
<td>25.2</td>
<td>18.5</td>
<td>9.38</td>
</tr>
<tr>
<td>MAX</td>
<td>78.4</td>
<td>81.7</td>
<td>77.1</td>
</tr>
<tr>
<td>P10</td>
<td>39.8</td>
<td>38.6</td>
<td>38.8</td>
</tr>
<tr>
<td>P25</td>
<td>46.2</td>
<td>45</td>
<td>44.3</td>
</tr>
<tr>
<td>P50</td>
<td>52</td>
<td>50.5</td>
<td>50</td>
</tr>
<tr>
<td>P75</td>
<td>59.6</td>
<td>57.4</td>
<td>56.1</td>
</tr>
<tr>
<td>P90</td>
<td>63.8</td>
<td>63</td>
<td>61.2</td>
</tr>
</tbody>
</table>

#### 2b6. Comparability of Multiple Data Sources/Methods. (If specified for more than one data source, the various approaches result in comparable scores.)

- **2b6.1 Data/Sample** *(Describe the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included):*

- **2b6.2 Analytic Method** *(Describe methods and rationale for testing comparability of scores produced by the different data sources specified in the measure):*

- **2b6.3 Testing Results** *(Provide statistical results, e.g., correlation statistics, comparison of rankings; assessment of adequacy in*
NQF #0031 Breast Cancer Screening

See Guidance for Definitions of Rating Scale: H=High; M=Moderate; L=Low; I=Insufficient; NA=Not Applicable

<table>
<thead>
<tr>
<th>2c. Disparities in Care:</th>
<th>H</th>
<th>M</th>
<th>L</th>
<th>I</th>
<th>NA</th>
<th>(If applicable, the measure specifications allow identification of disparities.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2c.1 If measure is stratified for disparities, provide stratified results (Scores by stratified categories/cohorts):</td>
<td>The measure is not stratified to detect disparities.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2c.2 If disparities have been reported/identified (e.g., in 1b), but measure is not specified to detect disparities, please explain:</td>
<td>NCQA has participated with IOM and others in attempting to include information on disparities in measure data collection. However, at the present time, this data, at all levels (claims data, paper chart review, and electronic records), is not coded in a standard manner, and is incompletely captured. There are no consistent standards for what entity (physician, group, plan, employer) should capture and report this data. While &quot;requiring&quot; reporting of the data could push this forward, it has been our position that doing so would create substantial burden with inability to use the data because of its inconsistency. At the present time, we agree with the IOM report that disparities are best considered by the use of zip code analysis which has limited applicability in most reporting situations. At the health plan level, for HEDIS health plan data collection, NCQA does have extensive data related to our use of stratification by insurance status (Medicare, Medicaid and private-commercial) and would strongly recommend this process where the data base supporting the measurement includes this information. However, we believe that the measure specifications should NOT require this since the measure is still useful where the data needed to determine disparities cannot be ascertained from the data available.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2.1-2.3 Supplemental Testing Methodology Information:

Steering Committee: Overall, was the criterion, Scientific Acceptability of Measure Properties, met? (Reliability and Validity must be rated moderate or high) Yes ☐ No ☐ Provide rationale based on specific subcriteria:

If the Committee votes No, STOP

3. USABILITY

Extent to which intended audiences (e.g., consumers, purchasers, providers, policy makers) can understand the results of the measure and are likely to find them useful for decision making. (evaluation criteria)

C.1 Intended Purpose/ Use (Check all the purposes and/or uses for which the measure is intended): Professional Certification or Recognition Program, Public Reporting, Quality Improvement (Internal to the specific organization), Quality Improvement with Benchmarking (external benchmarking to multiple organizations), Regulatory and Accreditation Programs

3.1 Current Use (Check all that apply; for any that are checked, provide the specific program information in the following questions): Public Reporting, Quality Improvement with Benchmarking (external benchmarking to multiple organizations)

3a. Usefulness for Public Reporting: H ☐ M ☐ L ☐ I ☐ (The measure is meaningful, understandable and useful for public reporting.)

3a.1. Use in Public Reporting - disclosure of performance results to the public at large (If used in a public reporting program, provide name of program(s), locations, Web page URL(s)). If not publicly reported in a national or community program, state the reason AND plans to achieve public reporting, potential reporting programs or commitments, and timeline, e.g., within 3 years of endorsement: [For Maintenance – If not publicly reported, describe progress made toward achieving disclosure of performance results to the public at large and expected date for public reporting; provide rationale why continued endorsement should be considered.]

This measure is used in public reporting for plans only through Healthcare Effectiveness Data and Information Set (HEDIS) and is reported through venues such as the annual State of Healthcare Quality report, Quality Compass, America’s Best Health Plans.
3a.2 Provide a rationale for why the measure performance results are meaningful, understandable, and useful for public reporting. If usefulness was demonstrated (e.g., focus group, cognitive testing), describe the data, method, and results: HEDIS measures adhere to the desirable attributes of scientific acceptability, feasibility and usability. The measures provide performance rates that are audited for consistency and accuracy.

3.2 Use for other Accountability Functions (payment, certification, accreditation). If used in a public accountability program, provide name of program(s), locations, Web page URL(s): NCQA reports on performance of health plans and providers nationally. Our results are not part of an internal NCQA QI program.

3b. Usefulness for Quality Improvement: H M L I
(The measure is meaningful, understandable and useful for quality improvement.)

3b.1. Use in QI. If used in quality improvement program, provide name of program(s), locations, Web page URL(s):
[For Maintenance – If not used for QI, indicate the reasons and describe progress toward using performance results for improvement].
This is a measure in the HEDIS measurement set and is used in NCQA's Health Plan Accreditation program.

3b.2. Provide rationale for why the measure performance results are meaningful, understandable, and useful for quality improvement. If usefulness was demonstrated (e.g., QI initiative), describe the data, method and results: HEDIS measures adhere to the desirable attributes of scientific acceptability, feasibility and usability. The measures provide performance rates that are audited for consistency and accuracy.

Overall, to what extent was the criterion, Usability, met? H M L I
Provide rationale based on specific subcriteria:

### 4. FEASIBILITY

Extent to which the required data are readily available, retrievable without undue burden, and can be implemented for performance measurement. (evaluation criteria)

4a. Data Generated as a Byproduct of Care Processes: H M L I

4a.1-2 How are the data elements needed to compute measure scores generated? (Check all that apply).
Data used in the measure are:
generated by and used by healthcare personnel during the provision of care, e.g., blood pressure, lab value, medical condition, Coded by someone other than person obtaining original information (e.g., DRG, ICD-9 codes on claims)

4b. Electronic Sources: H M L I

4b.1 Are the data elements needed for the measure as specified available electronically (Elements that are needed to compute measure scores are in defined, computer-readable fields): ALL data elements are in a combination of electronic sources

4b.2 If ALL data elements are not from electronic sources, specify a credible, near-term path to electronic capture, OR provide a rationale for using other than electronic sources:

4c. Susceptibility to Inaccuracies, Errors, or Unintended Consequences: H M L I

4c.1 Identify susceptibility to inaccuracies, errors, or unintended consequences of the measurement identified during testing and/or operational use and strategies to prevent, minimize, or detect. If audited, provide results:
All measures that are used in NCQA programs are audited.

4d. Data Collection Strategy/Implementation: H M L I

A.2 Please check if either of the following apply (regarding proprietary measures): Proprietary measure

4d.1 Describe what you have learned/modified as a result of testing and/or operational use of the measure regarding data collection, availability of data, missing data, timing and frequency of data collection, sampling, patient confidentiality, time and cost of data collection, other feasibility/implementation issues (e.g., fees for use of proprietary measures):
NQF #0031 Breast Cancer Screening

Overall, to what extent was the criterion, *Feasibility*, met? 

<table>
<thead>
<tr>
<th></th>
<th>H</th>
<th>M</th>
<th>L</th>
<th>I</th>
</tr>
</thead>
</table>

Provide rationale based on specific subcriteria:

**OVERALL SUITABILITY FOR ENDORSEMENT**

Does the measure meet all the NQF criteria for endorsement?  

<table>
<thead>
<tr>
<th></th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
</table>

Rationale:

If the Committee votes No, STOP.

If the Committee votes Yes, the final recommendation is contingent on comparison to related and competing measures.

**5. COMPARISON TO RELATED AND COMPETING MEASURES**

If a measure meets the above criteria and there are endorsed or new related measures (either the same measure focus or the same target population) or competing measures (both the same measure focus and the same target population), the measures are compared to address harmonization and/or selection of the best measure before a final recommendation is made.

5.1 If there are related measures (*either same measure focus or target population*) or competing measures (*both the same measure focus and same target population*), list the NQF # and title of all related and/or competing measures:

<table>
<thead>
<tr>
<th>Measure NQF #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>0623</td>
<td>Breast Cancer -Cancer Surveillance</td>
</tr>
</tbody>
</table>

5a. Harmonization

5a.1 If this measure has EITHER the same measure focus OR the same target population as NQF-endorsed measure(s):  
Are the measure specifications completely harmonized?  

|   | No |

5a.2 If the measure specifications are not completely harmonized, identify the differences, rationale, and impact on interpretability and data collection burden:

NA - the measures have a different focus and a different target population. Measure 0623 focuses on surveillance for women with a history of breast cancer. NCQA’s measure focuses on secondary prevention in a general population of women.

5b. Competing Measure(s)

5b.1 If this measure has both the same measure focus and the same target population as NQF-endorsed measure(s):
Describe why this measure is superior to competing measures (*e.g., a more valid or efficient way to measure quality*); OR provide a rationale for the additive value of endorsing an additional measure. *(Provide analyses when possible)*:

**CONTACT INFORMATION**

Co.1 Measure Steward (Intellectual Property Owner):  
National Committee for Quality Assurance, 1100 13th Street NW, Suite 1000, Washington, District Of Columbia, 20005

Co.2 Point of Contact:  
Bob, Rehm, Assistant Vice President, Performance Measurement, Rehm@ncqa.org, 202-955-1728-

Co.3 Measure Developer if different from Measure Steward:  
National Committee for Quality Assurance, 1100 13th Street NW, Suite 1000, Washington, District Of Columbia, 20005

Co.4 Point of Contact:  
Bob, Rehm, Assistant Vice President, Performance Measurement, Rehm@ncqa.org, 202-955-1728-

Co.5 Submitter:  
Dawn, Alayon, MPH, CPH, Senior Health Care Analyst, alayon@ncqa.org, 202-955-3533-, National Committee for Quality Assurance

Co.6 Additional organizations that sponsored/participated in measure development:

Co.7 Public Contact:  
Bob, Rehm, Assistant Vice President, Performance Measurement, Rehm@ncqa.org, 202-955-1728-, National Committee for Quality Assurance
## ADDITIONAL INFORMATION

### Workgroup/Expert Panel involved in measure development

**Ad.1** Provide a list of sponsoring organizations and workgroup/panel members' names and organizations. Describe the members' role in measure development.

The NCQA Breast Cancer MAP advised NCQA during measure development. They evaluated the way staff specified measures, assessed the content validity of measures, and reviewed field test results. As you can see from the list, the MAP consisted of a balanced group of experts. Note that, in addition to the MAP, we also vetted these measures with a host of other stakeholders, as is our process. Thus, our measures are the result of consensus from a broad and diverse group of stakeholders, in addition to the MAP.

Kathy Cotlin, MPH  
Lance Lang, MD  
Dorothy Mann, PhD  
Saralyn Mark, MD Phone: 202-230-4101  
Robin Richman, MD, FACOG  
Robert Smith, PhD  
Eric Tangalos, MD

### Measure Developer/Steward Updates and Ongoing Maintenance

**Ad.2** If adapted, provide title of original measure, NQF # if endorsed, and measure steward. Briefly describe the reasons for adapting the original measure and any work with the original measure steward: **NA**

### Date of Submission (MM/DD/YY): 07/12/2011